The authors investigated the therapeutic potential of the AXL inhibitor BGB324 alone or in combination with the clinically relevant BRAF inhibitor vemurafenib.
[Scientific Reports]
Sorry, but the selected Zotpress account can't be found.
Sorry, but the selected Zotpress account can't be found.
